Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. Pacific Time in San Francisco. Kyle Gano, Chief Executive Officer, will deliver the presentation.

The live webcast can be accessed via the company's Investors website at neurocrine.com. A replay will be posted approximately one hour after the event and archived for about one month.

Neurocrine is a neuroscience-focused biopharmaceutical company with FDA-approved treatments across tardive dyskinesia, Huntington's chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids (collaboration with AbbVie), and a mid- to late-stage clinical pipeline.

News Market Reaction – NBIX

+1.00%

2 alerts

+1.00% Session close to close

$13.39B Market Cap

0.1x Rel. Volume

In the Jan 6 session, NBIX gained 1.00%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on NBIX presenting at the 44th J.P. Morgan Healthcare Conference, adding a...

Analysis

This announcement centers on NBIX presenting at the 44th J.P. Morgan Healthcare Conference, adding another platform to communicate its neuroscience strategy and commercial portfolio. Against a backdrop of strong Q3 2025 financials and mixed recent clinical outcomes, the event offers management a chance to frame pipeline priorities and capital allocation. Investors may focus on any new commentary around late‑stage programs, commercial execution, and how the company positions its diverse portfolio across neurological and endocrine indications.

Key Figures

Q3 2025 revenue: $794.9M Q3 2024 revenue: $622.1M INGREZZA net sales: $686.6M +5 more

8 metrics

Q3 2025 revenue $794.9M Total revenues in Q3 2025

Q3 2024 revenue $622.1M Total revenues a year ago for comparison

INGREZZA net sales $686.6M Q3 2025 net product sales

CRENESSITY launch sales $98.1M Q3 2025 U.S. launch contribution

Q3 2025 operating income $239.0M Operating income in Q3 2025

Q3 2025 net income $209.5M Net income in Q3 2025

Diluted EPS Q3 2025 $2.04 Versus $1.24 a year earlier

Cash & securities $2,113.3M Cash, cash equivalents and marketable securities as of 09/30/2025

Historical Context

5 past events · Latest: Dec 22 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 22	Phase 3 trial update	Negative	-0.2%	Phase 3 KINECT‑DCP study failed to meet primary and key secondary endpoints.
Dec 16	R&D strategy update	Positive	-4.7%	Outlined transformed R&D strategy with multiple late‑stage milestones and new programs.
Dec 09	R&D Day announcement	Neutral	+0.4%	Announced upcoming R&D Day to highlight pipeline and feature a key opinion leader.
Nov 20	Publication highlight	Positive	+0.7%	Narrative review showed distinctive profile for INGREZZA among FDA‑approved VMAT2 inhibitors.
Nov 18	Phase 2 trial results	Positive	-3.4%	Phase 2 SAVITRI trial showed significant benefit for 1 mg osavampator in depression.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

NBIX has shown mixed reactions to news: clear positive clinical and R&D updates have sometimes been followed by share price declines, while other scientific or publication milestones saw modest gains.

Recent Company History

Over the last few months, NBIX reported a failed Phase 3 KINECT‑DCP trial, a transformed R&D strategy with multiple late‑stage readouts targeted for 2027–2028, and detailed R&D Day presentations. It also highlighted a distinctive clinical and pharmacologic profile for INGREZZA and released positive Phase 2 SAVITRI data for osavampator in major depressive disorder. Price reactions have varied, with some positive updates followed by declines, suggesting investors weigh long‑term pipeline potential against near‑term trial and portfolio risks.

Key Terms

tardive dyskinesia, Huntington's disease, congenital adrenal hyperplasia, endometriosis, +3 more

7 terms

tardive dyskinesia medical

"FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease..."

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

Huntington's disease medical

"FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease..."

A hereditary brain disorder caused by a faulty gene that progressively damages nerve cells, leading to uncontrollable movements, thinking and mood problems, and a shortened lifespan. It matters to investors because the disease creates a clear medical need and potential market for treatments, so news about clinical trial results, regulatory progress, or drug approvals can strongly move biotech and pharmaceutical stock values. Think of it as a predictable, inherited mechanical flaw in a complex machine that companies are trying to fix.

congenital adrenal hyperplasia medical

"treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia..."

Congenital adrenal hyperplasia is a group of inherited disorders in which the adrenal glands lack an enzyme needed to make certain hormones, causing a chronic imbalance of cortisol, aldosterone and/or sex hormones. Think of it as a factory assembly line missing a key part, so the body overproduces some products and underproduces others, requiring lifelong monitoring or hormone treatment. For investors, it matters because diagnosis, ongoing therapy, newborn screening and potential new drugs or gene therapies can drive medical spending, regulatory approvals and market opportunity in endocrinology and rare disease care.

endometriosis medical

"classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*..."

Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility problems. It can impact a person's health and quality of life, potentially leading to increased healthcare costs and affecting workforce productivity. For investors, understanding conditions like endometriosis highlights the importance of healthcare innovations and markets related to women's health.

uterine fibroids medical

"classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*..."

Uterine fibroids are noncancerous growths that develop in the muscular wall of the uterus, often described like small rubbery lumps within the organ. They matter to investors because they affect a large number of people of reproductive age and drive demand for diagnostics, medications, minimally invasive procedures and surgical devices, creating revenue opportunities and regulatory, reimbursement and competitive considerations for healthcare companies.

neuroendocrine medical

"under-addressed neurological, neuroendocrine and neuropsychiatric disorders."

Neuroendocrine describes cells and processes where the nervous system and the hormone system meet: certain nerve-linked cells release chemical messengers (hormones) into the bloodstream in response to nerve signals, acting like a thermostat wired to both a sensor and a heater. Investors care because neuroendocrine functions are central to a class of diseases and treatments—diagnostics, drugs, and devices aimed at these pathways can drive regulatory milestones, revenue potential, and valuation changes for healthcare companies.

neuropsychiatric medical

"under-addressed neurological, neuroendocrine and neuropsychiatric disorders."

Conditions or symptoms that involve both the brain’s biology and a person’s mood, thinking or behavior; they sit at the intersection of neurology and psychiatry. Investors care because neuropsychiatric issues often require specialized drugs, devices or diagnostics, carry distinct regulatory and safety risks, and can affect patient populations and market size — think of them as disorders where hardware (brain circuitry) and software (behavior) problems overlap.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44^th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January 12, 2026, in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.

The live presentation will be webcast and can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.
(*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302653067.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences (NBIX) present at the 44th J.P. Morgan Healthcare Conference?

Neurocrine will present on Monday, January 12, 2026 at 9:45 a.m. Pacific Time.

Who will present for Neurocrine Biosciences (NBIX) at JP Morgan on January 12, 2026?

Kyle Gano, Chief Executive Officer will present on behalf of Neurocrine.

How can investors watch the Neurocrine (NBIX) presentation live or on replay?

The presentation will be webcast live on neurocrine.com under Investors; a replay posts about one hour after the event and is archived for ~one month.

What FDA-approved treatments does Neurocrine Biosciences (NBIX) list in the announcement?

The announcement lists approvals for tardive dyskinesia, Huntington's chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids (endometriosis and uterine fibroids in collaboration with AbbVie).

Will the Neurocrine (NBIX) webcast replay remain available after the JP Morgan presentation?

Yes, the replay will be archived on the company's website for approximately one month after posting.